Cargando…

Specification of drug substances and products : development and validation of analytical methods /

Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of a...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Riley, Christopher M., Rosanske, Thomas W., Riley, Shelley R. Rabel
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Elsevier, [2014]
Colección:Progress in pharmaceutical and biomedical analysis.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 EBSCO_ocn861537317
003 OCoLC
005 20231017213018.0
006 m o d
007 cr cn|||||||||
008 131008t20142014ne a ob 001 0 eng d
040 |a E7B  |b eng  |e rda  |e pn  |c E7B  |d N$T  |d OPELS  |d YDXCP  |d OCLCF  |d GGVRL  |d UWO  |d EBLCP  |d UKDOC  |d OCLCQ  |d USU  |d OCLCO  |d ICA  |d OCLCA  |d OCLCO  |d LVT  |d OCLCQ  |d COCUF  |d AGLDB  |d K6U  |d PIFAG  |d FVL  |d ZCU  |d OCLCO  |d MERUC  |d OCLCO  |d SAV  |d OCLCO  |d U3W  |d OCLCA  |d STF  |d D6H  |d OCLCQ  |d VTS  |d VT2  |d OCLCQ  |d WYU  |d OCLCO  |d TKN  |d DKC  |d OCLCO  |d OCLCQ  |d M8D  |d OCLCQ  |d OCLCA  |d AJS  |d OCLCO  |d OCLCQ  |d OCLCO 
015 |a GBB358820  |2 bnb 
016 7 |a 016448212  |2 Uk 
019 |a 863821936  |a 880437636  |a 1055393858  |a 1065703744  |a 1071485121  |a 1081234603 
020 |a 9780080983431  |q (electronic bk.) 
020 |a 008098343X  |q (electronic bk.) 
020 |z 9780080983509 
020 |z 0080983502  |q (hbk.) 
029 1 |a AU@  |b 000059642881 
029 1 |a AU@  |b 000060553554 
029 1 |a DEBBG  |b BV043216080 
029 1 |a DEBBG  |b BV044063585 
029 1 |a DEBSZ  |b 405351305 
029 1 |a DEBSZ  |b 481276637 
029 1 |a NLGGC  |b 370258916 
035 |a (OCoLC)861537317  |z (OCoLC)863821936  |z (OCoLC)880437636  |z (OCoLC)1055393858  |z (OCoLC)1065703744  |z (OCoLC)1071485121  |z (OCoLC)1081234603 
050 4 |a RS189  |b .S64 2014eb 
060 4 |a QV 771 
072 7 |a MED  |x 071000  |2 bisacsh 
082 0 4 |a 615.19 
049 |a UAMI 
245 0 0 |a Specification of drug substances and products :  |b development and validation of analytical methods /  |c edited by Christopher M. Riley, Riley and Rabel Consulting Services, Maryville, MO, USA, Thomas W. Rosanske, T.W. Rosanske Consulting, Overland Park, KS, USA, Shelley R, Rabel Riley, Department of Natural Sciences, Northwest Missouri State University, Maryville, MO, USA ; Riley and Rabel Consulting Services, Maryville, MO, USA. 
264 1 |a Amsterdam :  |b Elsevier,  |c [2014] 
264 4 |c ©2014 
300 |a 1 online resource (389 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Progress in Pharmaceutical and Biomedical Analysis 
504 |a Includes bibliographical references and index. 
505 0 |a Part 1. Introduction -- part 2. Universal tests -- part 3. Specific tests : drug substance -- part 4. Specific tests : drug product -- part 5. Pharmacopeial methods -- part 6. Microbial methods -- part 7. Biological fluids. 
588 0 |a Online resource; title from PDF title page (ebrary, viewed October 8, 2013). 
520 |a Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of analytical methods. This book is intended as more than a review of new regional guidelines, existing regulatory guidance, and industry practices. It provides a hands-on guide to understanding and applying these in practice. The authors discuss critical issues, novel approaches, and future directions while also providing insight into how International Guidelines were developed and the rationale behind them. Guide to industry best practices of analytical methodologies used in the specification of new drug substances and products (e.g. DOE, QbD)Critical assessment of the application of ICH guidelines on method validation and specification setting, written by experts involved in the development and application of the guidelines to aid understanding of requirements and what is expected by regulatory authoritiesDirect applicability to the day-to-day activities in drug development and the potential to increase productivity. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Drugs  |x Analysis  |x Methodology. 
650 2 |a Pharmaceutical Preparations  |x methods 
650 2 |a Pharmaceutical Preparations  |x standards 
650 6 |a Médicaments  |x Analyse  |x Méthodologie. 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a Drugs  |x Analysis  |x Methodology  |2 fast 
700 1 |a Riley, Christopher M. 
700 1 |a Rosanske, Thomas W. 
700 1 |a Riley, Shelley R. Rabel. 
776 0 8 |i Print version:  |t Specification of drug substances and products.  |d Amsterdam : Elsevier, 2014  |z 9780080983509  |w (DLC) 2013444132 
830 0 |a Progress in pharmaceutical and biomedical analysis. 
856 4 0 |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=486507  |z Texto completo 
936 |a BATCHLOAD 
938 |a 123Library  |b 123L  |n 109351 
938 |a EBL - Ebook Library  |b EBLB  |n EBL1418374 
938 |a ebrary  |b EBRY  |n ebr10771956 
938 |a EBSCOhost  |b EBSC  |n 486507 
938 |a Cengage Learning  |b GVRL  |n GVRL8EBF 
938 |a YBP Library Services  |b YANK  |n 11211364 
994 |a 92  |b IZTAP